10-QPeriod: Q3 FY2006

CARDINAL HEALTH INC Quarterly Report for Q3 Ended Mar 31, 2006

Filed May 8, 2006For Securities:CAH

Summary

Cardinal Health, Inc. reported its financial results for the nine months ended March 31, 2006. Total revenue for the nine months increased by 9% to $59.7 billion, driven by growth across all reportable segments, particularly in Pharmaceutical Distribution and Provider Services. However, net earnings saw a significant decline of 14% to $679.1 million compared to the same period last year, primarily due to substantial losses from discontinued operations and increased selling, general, and administrative expenses, including a significant rise in equity-based compensation due to the adoption of SFAS No. 123(R). The company is undergoing significant restructuring and integration efforts, including a global restructuring program aimed at improving efficiency. The company is also navigating several legal and regulatory investigations, including an SEC investigation, and has reached an agreement-in-principle for a $35 million penalty. These factors, combined with changes in senior management, including the appointment of a new CEO, create a complex operating environment. Investors should monitor the company's ability to execute its restructuring plans, resolve ongoing investigations, and manage the impact of regulatory changes on its core businesses.

Key Highlights

  • 1Total revenue increased by 9% year-over-year for the nine months ended March 31, 2006, reaching $59.7 billion, indicating continued top-line growth across business segments.
  • 2Net earnings experienced a significant 14% decrease for the nine-month period, falling to $679.1 million, heavily impacted by substantial losses from discontinued operations and increased operating expenses.
  • 3The company is actively engaged in a global restructuring program, with significant costs incurred for business consolidations, process improvements, and workforce reductions, expected to be substantially completed by the end of fiscal 2008.
  • 4Equity-based compensation expense increased dramatically due to the adoption of SFAS No. 123(R), impacting reported earnings, with total expense for the nine months rising to $185.2 million from $7.2 million in the prior year.
  • 5Cardinal Health is subject to an ongoing SEC investigation and other regulatory inquiries, with an agreement-in-principle reached for a $35 million penalty, though final settlement terms and potential additional liabilities remain uncertain.
  • 6Significant assets and businesses have been classified as held for sale or discontinued operations, including portions of the Healthcare Marketing Services business and the United Kingdom-based Intercare Pharmaceutical Distribution business, leading to substantial impairment charges.
  • 7The company announced leadership changes, appointing R. Kerry Clark as President and CEO, and Robert D. Walter as Executive Chairman, signaling a transition in executive management.

Frequently Asked Questions

For the nine months ended March 31, 2006, Cardinal Health reported a 9% increase in revenue to $59.7 billion, reflecting growth across its segments. However, net earnings decreased by 14% to $679.1 million compared to the same period in the prior year. This decline was primarily attributed to significant losses from discontinued operations and higher operating expenses, including increased equity-based compensation.

Discontinued operations had a significant negative impact on earnings. The company reported losses from discontinued operations of $226.8 million for the nine months ended March 31, 2006, compared to a loss of $12.7 million in the prior year. This was largely due to impairment charges related to businesses held for sale, such as the Healthcare Marketing Services and Intercare Pharmaceutical Distribution businesses.

Key challenges include the ongoing SEC investigation and other regulatory inquiries, which could result in additional penalties or sanctions. The company is also undergoing a major global restructuring program that involves significant costs and potential disruptions. Furthermore, changes in senior management and recent legislative changes affecting Medicaid reimbursement present strategic and operational risks.

The adoption of SFAS No. 123(R) in the first quarter of fiscal 2006 requires the expensing of equity-based compensation at fair value. This significantly increased equity-based compensation expense, negatively impacting operating earnings. For the nine months ended March 31, 2006, this expense was $185.2 million, a substantial increase from $7.2 million in the prior year's comparable period.